Nanoscale Liquid Biopsy Technique Reveals More About Cancer

Something intriguing occurs when nanoparticles come into contact with biological fluids: proteins attach themselves to the nanoparticle surfaces, forming what is called a "protein corona." This phenomenon has now resulted in a technique that could allow doctors and researchers to glean additional information from the blood of cancer patients. When researchers from the University of Manchester extracted injected liposomes—lipid-based nanoparticles used for drug delivery with minimal side effects—...
Continue reading

Early-Stage Ovarian Cancer Detected by Blood Test

With a 20% five-year survival rate, advanced ovarian cancer is one of the deadliest diseases. When women are diagnosed in stages I and II, however, the five-year survival rate increases to 90%. Unfortunately, only 15% of ovarian cancer cases are discovered in the early stages due to lack of symptoms and a dearth of tests for ovarian cancer biomarkers. Researchers at the University of Adelaide and Griffith University in Australia have found a potential new method to detect early-stage disease by ...
Continue reading

Reduced Risk of Ovarian Cancer With Low-Dose Aspirin Use

A new study conducted by Moffitt Cancer Center in conjunction with Huntsman Cancer Institute and Harvard T.H. Chan School of Public Health found that women who take low-dose aspirin daily are at lower risk of developing ovarian cancer. The findings, published online by JAMA Oncology, also show that women who take at least 10 tablets per week of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen over many years are at an increased risk of developing ovarian can...
Continue reading

Ovarian Cancer: Researchers Predict PARP Inhibitor Response

​Researchers have found a way to identify which patients with high-grade serous ovarian carcinoma (HGSOC), the most malignant and most common form of ovarian cancer, will respond to poly (ADP-ribose) polymerase (PARP) inhibitor therapy. The answer to this question, as addressed in a study published in Nature Communications, could allow doctors to tailor patients' therapy on an individual basis, facilitating better treatment responses and increased chances of survival. Mutations of two BRCA genes...
Continue reading

New Tactic Launches Dual-Pronged Attack on Ovarian Tumor Cells

In a new approach to combatting ovarian cancer, a paper published in Cancer Cell describes an engineered antibody able to launch a dual-pronged assault on tumor cells. A primary difficulty with immunotherapy for ovarian cancer is that therapeutic antibodies cannot effectively penetrate the solid tumor bed. According to senior author Jogender Tushir-Singh, PhD, assistant professor of biochemistry and genetics at the University of Virginia School of Medicine, the solid tumor microenvironment ...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.